Mistral Accelerates Research: New Clinical Trials Launched Across Italy

Friday March 7th, 2025

The year 2024 marks a crucial milestone for Mistral, with the launch of major clinical trials in collaboration with centers of excellence throughout Italy.

Mistral is a certified medical device (CEE 93/42) that captures volatile organic compounds (VOCs) in human breath with a simple exhalation. Thanks to advanced analysis performed by the Mistral Lab, these compounds are identified to trace each individual’s metabolic fingerprint, providing valuable insights into their physiopathological condition.

In 2024, Mistral technology has been integrated into several clinical trials aimed at investigating the role of VOCs in the early screening of various diseases.

As of October 2024, new trials have been launched at the following hospitals and medical centers:

  • Miulli Hospital (Acquaviva): study on prostate cancer
  • IFO – Istituti Fisioterapici Ospedalieri (Rome): trial on head and neck cancers
  • LUCEA Multimedica Center (Monopoli): clinical study on colorectalcancer
  • Rete Salute Calabrese Institute: clinical trial on lungcancer

The results from 2024 represent a decisive step toward the wider adoption of Mistral technologies in medical research. Thanks to strong collaboration with leading healthcare institutions, 2025 is set to be a key year to consolidate the progress made and to demonstrate the full potential of breath analysis in the early screening of various diseases.

Articoli correlati

News
News

Artificial Intelligence in Medicine: Predict Joins Salento Biomedical District Event with Mistral Technologies

Wednesday June 25th, 2025

On June 19, 2025, we were among the key participants at the event “Artificial Intelligence in Medicine: From Innovation to Clinical Practice”, organized by the Salento Biomedical District in collaboration with UniSalento and the Italian Institute of Technology. The event was designed to bridge the gap between healthcare and innovation, bringing together medical professionals, companies, […]

Predict Partners in the Endoscope Project for Early Diagnosis of Colorectal Cancer

Monday February 10th, 2025

Predict is participating, alongside the University of Bari and the University of Salento, in the Endoscope project, funded under the “D3-4Health” cascade calls promoted by Sapienza University of Rome. D3-4Health (Digital Driven Diagnostics, Prognostics and Therapeutics for Sustainable Healthcare) is an initiative involving 28 public and private entities, with the aim of developing advanced digital […]
My Agile Privacy
✕
This website uses technical and profiling cookies. Clicking on "Accept" authorises all profiling cookies. Clicking on "Refuse" or the X will refuse all profiling cookies. By clicking on "Customise" you can select which profiling cookies to activate.
AcceptRefuseCustomize
Warning: some page functionalities could not work due to your privacy choices